Last reviewed · How we verify
NCT07047183
Clinical Study of Venetoclax Combined With Azacitidine as Bridging Therapy Prior to Hematopoietic Stem Cell Transplantation in Patients With Higher-Risk Myelodysplastic Syndromes
Phase 2 trial testing VEN (Venetoclax) in Myelodysplastic Neoplasms in 46 participants. Currently enrolling.
30 June 2029
Quick facts
| Lead sponsor | Yehui Tan |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 46 |
| Start date | 1 July 2025 |
| Primary completion | 30 June 2029 |
| Estimated completion | 30 June 2029 |
| Sites | 1 location across China |
Drugs / interventions tested
- VEN (Venetoclax) — full drug profile →
Conditions studied
- Myelodysplastic Neoplasms — all drugs for Myelodysplastic Neoplasms →
- Transplantation — all drugs for Transplantation →
Sponsor
Yehui Tan — full company profile →
Who can join
18 and older, any sex, with Myelodysplastic Neoplasms or Transplantation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A Single-Arm, Prospective Clinical Study of Venetoclax Combined with Azacitidine Followed by Bridging Transplantation in Patients with High-Risk Myelodysplastic Neoplasms with Increased Blasts 2 (MDS-IB2)
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07047183
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of VEN (Venetoclax)
Trials testing the same drug.
- NCT07159620 — Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients · Phase 2 · recruiting
- NCT03295240 — The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma · EARLY_PHASE1 · completed
Other recruiting trials for Myelodysplastic Neoplasms
Currently open trials in the same condition.
- NCT06651229 — A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms · Phase 1 · recruiting
- NCT06618001 — A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms · Phase 1 · recruiting
Other Yehui Tan trials
Trials by the same sponsor.
- NCT06990321 — Effectiveness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation Therapy in Elderly Patients With Inte · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07047183 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Yehui Tan
- Last refreshed: 8 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07047183.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing